GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Notes Receivable

Frontage Holdings (HKSE:01521) Notes Receivable : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Notes Receivable?

Frontage Holdings's Notes Receivable for the quarter that ended in Dec. 2023 was HK$0 Mil.


Frontage Holdings Notes Receivable Historical Data

The historical data trend for Frontage Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Notes Receivable Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Frontage Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Frontage Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines